Press Room
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
11/06/2018
Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). The role of cabozantinib has not been established in non-clear cell renal cell carcinoma (nccRCC).
Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
10/30/2018
EUSA Pharma (EUSA) welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.
Sunitinib vs Nephrectomy Followed by Sunitinib in Metastatic Renal Cell Carcinoma
10/30/2018
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, and colleagues found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.
Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
10/29/2018
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P < .0001). Median progression-free survival was 11.6 vs 8.4 months (HR = 0.82, P = not significant). The objective response rate was 41.6% vs 26.5% (P < .0001). The efficacy of the combination was not established in patients with favorable-risk disease.
Combination immunotherapy with IL-2 surface-modified tumor cell vaccine and PD-1 blockade against renal cell carcinoma
10/29/2018
Studies show that immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma.
Eating Organic Food May Reduce Cancer Risk
10/25/2018
A new study published in JAMA Internal Medicine suggests those who frequently eat organic foods may have a lower risk of developing cancer.
Tall people at greater risk of cancer, study says
10/25/2018
Colon and kidney cancer and lymphoma were among the types of cancer for which the correlation was strongest.
8 Surprising Health Benefits of Wakame Seaweed
10/12/2018
Wakame seaweed may have cancer-fighting properties. A study found that specific compounds extracted from the seaweed were effective at inhibiting the growth of colon and kidney cancer cells.
LoginSearchLATEST A look ahead to key trial readouts at ESMO
10/12/2018
ESMO is only 7 days away. Here is an inside look at some of the trials that will be discussed.
Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
10/09/2018
Cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23, 2018 in Munich, Germany.
News Feed| NeonCRM by Neon One |